Optiscan Imaging Limited engages in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications in Australia, Germany, and Internationally. It offers InVivage, an intra-oral digital hand-held confocal endomicroscope for oral cancer screening and/or surgical margin determination; and ViewnVivo, a miniaturized in vivo imaging device that offers single-cell 3D live microscopic imaging. The company was founded in 1994 and is headquartered in Mulgrave, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.10486293399723973 | N/A |
Market Cap | $87.60M | N/A |
Shares Outstanding | 835.34M | 32.36% |
Employees | 0 | N/A |
Shareholder Equity | 3.04M | -53.82% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 77.06 | N/A |
P/B Ratio | 28.77 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.9670 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $1.14M | N/A |
Earnings | -$2.94M | N/A |
Gross Margin | 0.671 | N/A |
Operating Margin | -3.15 | N/A |
Net income margin | -2.59 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $3.16M | N/A |
Total Debt | $278.93K | N/A |
Cash on Hand | $628.49K | N/A |
Debt to Equity | 0.3617 | 153.24% |
Cash to Debt | $2.25 | -72.70% |
Current Ratio | $2.56 | -65.00% |